Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18371908 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2TAAR1KMT2AAKR1B1ALDH1A1 | |
| SCHEMBL18184977 | 0.87 | ALDH1A1 (0.42) | SMN1; SMN2TAAR1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL18371893 | 0.87 | TAAR1 (0.50) | SMN1; SMN2TAAR1KMT2AALDH1A1HTT | |
| SCHEMBL19055337 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1KMT2AAKR1B1ALDH1A1 | |
| SCHEMBL5667835 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1KMT2AAKR1B1ALDH1A1 | |
| SCHEMBL18371912 | 0.82 | P2RX7 (0.41) | TAAR1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19055367 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2TAAR1KMT2AAKR1B1ALDH1A1 | |
| SCHEMBL19098941 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2TAAR1KMT2AAKR1B1ALDH1A1 | |
| SCHEMBL18185057 | 0.80 | LMNA (0.45) | SMN1; SMN2KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19055368 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2TAAR1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | LYCERA CORPORATION | 2018-04-26 | — | — | US | disclosed |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | LYCERA CORPORATION | 2018-04-26 | — | — | US | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-9802958-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802958-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-01-12 | — | — | US | disclosed |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-11-03 | — | — | US | disclosed |
| US-9394315-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | RORB, RORA, RORC | SMN1; SMN2 2315/4885TAAR1 1006/4885KMT2A 1546/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | SMN1; SMN2 2195/4885TAAR1 1023/4885KMT2A 1372/4885 |
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORB, RORA | SMN1; SMN2 2811/4885TAAR1 894/4885KMT2A 2706/4885 |
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORC, RORA, RORB | SMN1; SMN2 2301/4885TAAR1 742/4885KMT2A 1580/4885 |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | SMN1; SMN2 2304/4885TAAR1 610/4885KMT2A 1517/4885 |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | RORC, RORA, RORB | SMN1; SMN2 3033/4885TAAR1 442/4885KMT2A 1988/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | SMN1; SMN2 2195/4885TAAR1 1023/4885KMT2A 1372/4885 |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | SMN1; SMN2 2075/4885TAAR1 1826/4885KMT2A 1579/4885 |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | SMN1; SMN2 3028/4885TAAR1 779/4885KMT2A 2458/4885 |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | SMN1; SMN2 1570/4885TAAR1 782/4885KMT2A 939/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | SMN1; SMN2 1570/4885TAAR1 782/4885KMT2A 939/4885 |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | SMN1; SMN2 2230/4885TAAR1 503/4885KMT2A 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.